Recent News for ARVN - Arvinas, Inc.

Date Title
Aug 16 David Swensen Sells DocuSign in 2nd quarter
Aug 7 Arvinas To Present at the Wedbush PacGrow Healthcare Conference
Aug 6 JPMorgan upgrades Insulet after strong Q2
Aug 5 Arvinas EPS misses by $0.14, beats on revenue
Aug 5 Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 31 Steven Cohen Charges Into Chiasma
Jul 29 Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer
Jul 25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk
Jul 18 Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference
Jul 5 48 Biggest Movers From Wednesday
Jun 27 Will Arvinas Continue to Surge Higher?
Jun 26 Is Arvinas, Inc. (ARVN) A Good Stock To Buy?
Jun 25 Arvinas on go with early-stage study of ARV-471 in breast cancer
Jun 25 Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
Jun 20 Arvinas to Present at the BMO Prescriptions for Success Healthcare Conference
Jun 12 Arvinas (ARVN) Investor Presentation - Slideshow
Jun 11 48 Stocks Moving In Tuesday's Mid-Day Session
Jun 6 Arvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Jun 5 Benzinga's Top Upgrades, Downgrades For June 5, 2019
Jun 4 Bayer teams up with Arvinas in crop protection
Jun 4 Bayer and Arvinas to Collaborate on Human PROTAC® Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC® Applications
Jun 4 Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plants
May 29 Arvinas' ARV-110 Fast Track'd for mCRPC
May 29 Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer
May 11 Did Hedge Funds Drop The Ball On Arvinas, Inc. (ARVN) ?
Back to the Main ARVN Page...